Cargando…

ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction

AIMS: The prevalence of heart failure with preserved ejection fraction (HFpEF) is still increasing, and so far, no pharmaceutical treatment has proven to be effective. A key obstacle for testing new pharmaceutical substances is the availability of suitable animal models for HFpEF, which realisticall...

Descripción completa

Detalles Bibliográficos
Autores principales: Schauer, Antje, Draskowski, Runa, Jannasch, Anett, Kirchhoff, Virginia, Goto, Keita, Männel, Anita, Barthel, Peggy, Augstein, Antje, Winzer, Ephraim, Tugtekin, Malte, Labeit, Siegfried, Linke, Axel, Adams, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524062/
https://www.ncbi.nlm.nih.gov/pubmed/32710530
http://dx.doi.org/10.1002/ehf2.12915
_version_ 1783588481045364736
author Schauer, Antje
Draskowski, Runa
Jannasch, Anett
Kirchhoff, Virginia
Goto, Keita
Männel, Anita
Barthel, Peggy
Augstein, Antje
Winzer, Ephraim
Tugtekin, Malte
Labeit, Siegfried
Linke, Axel
Adams, Volker
author_facet Schauer, Antje
Draskowski, Runa
Jannasch, Anett
Kirchhoff, Virginia
Goto, Keita
Männel, Anita
Barthel, Peggy
Augstein, Antje
Winzer, Ephraim
Tugtekin, Malte
Labeit, Siegfried
Linke, Axel
Adams, Volker
author_sort Schauer, Antje
collection PubMed
description AIMS: The prevalence of heart failure with preserved ejection fraction (HFpEF) is still increasing, and so far, no pharmaceutical treatment has proven to be effective. A key obstacle for testing new pharmaceutical substances is the availability of suitable animal models for HFpEF, which realistically reflect the clinical picture. The aim of the present study was to characterize the development of HFpEF and skeletal muscle (SM) dysfunction in ZSF1 rats over time. METHODS AND RESULTS: Echocardiography and functional analyses of the SM were performed in 6‐, 10‐, 15‐, 20‐, and 32‐week‐old ZSF1‐lean and ZSF1‐obese. Furthermore, myocardial and SM tissue was collected for molecular and histological analyses. HFpEF markers were evident as early as 10 weeks of age. Diastolic dysfunction, confirmed by a significant increase in E/e′, was detectable at 10 weeks. Increased left ventricular mRNA expression of collagen and BNP was detected in ZSF1‐obese animals as early as 15 and 20 weeks, respectively. The loss of muscle force was measurable in the extensor digitorum longus starting at 15 weeks, whereas the soleus muscle function was impaired at Week 32. In addition, at Week 20, markers for aortic valve sclerosis were increased. CONCLUSIONS: Our measurements confirmed the appearance of HFpEF in ZSF1‐obese rats as early as 10 weeks of age, most likely as a result of the pre‐existing co‐morbidities. In addition, SM function was reduced after the manifestation of HFpEF. In conclusion, the ZSF1 rat may serve as a suitable animal model to study pharmaceutical strategies for the treatment of HFpEF.
format Online
Article
Text
id pubmed-7524062
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75240622020-10-02 ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction Schauer, Antje Draskowski, Runa Jannasch, Anett Kirchhoff, Virginia Goto, Keita Männel, Anita Barthel, Peggy Augstein, Antje Winzer, Ephraim Tugtekin, Malte Labeit, Siegfried Linke, Axel Adams, Volker ESC Heart Fail Original Research Articles AIMS: The prevalence of heart failure with preserved ejection fraction (HFpEF) is still increasing, and so far, no pharmaceutical treatment has proven to be effective. A key obstacle for testing new pharmaceutical substances is the availability of suitable animal models for HFpEF, which realistically reflect the clinical picture. The aim of the present study was to characterize the development of HFpEF and skeletal muscle (SM) dysfunction in ZSF1 rats over time. METHODS AND RESULTS: Echocardiography and functional analyses of the SM were performed in 6‐, 10‐, 15‐, 20‐, and 32‐week‐old ZSF1‐lean and ZSF1‐obese. Furthermore, myocardial and SM tissue was collected for molecular and histological analyses. HFpEF markers were evident as early as 10 weeks of age. Diastolic dysfunction, confirmed by a significant increase in E/e′, was detectable at 10 weeks. Increased left ventricular mRNA expression of collagen and BNP was detected in ZSF1‐obese animals as early as 15 and 20 weeks, respectively. The loss of muscle force was measurable in the extensor digitorum longus starting at 15 weeks, whereas the soleus muscle function was impaired at Week 32. In addition, at Week 20, markers for aortic valve sclerosis were increased. CONCLUSIONS: Our measurements confirmed the appearance of HFpEF in ZSF1‐obese rats as early as 10 weeks of age, most likely as a result of the pre‐existing co‐morbidities. In addition, SM function was reduced after the manifestation of HFpEF. In conclusion, the ZSF1 rat may serve as a suitable animal model to study pharmaceutical strategies for the treatment of HFpEF. John Wiley and Sons Inc. 2020-07-25 /pmc/articles/PMC7524062/ /pubmed/32710530 http://dx.doi.org/10.1002/ehf2.12915 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Schauer, Antje
Draskowski, Runa
Jannasch, Anett
Kirchhoff, Virginia
Goto, Keita
Männel, Anita
Barthel, Peggy
Augstein, Antje
Winzer, Ephraim
Tugtekin, Malte
Labeit, Siegfried
Linke, Axel
Adams, Volker
ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title_full ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title_fullStr ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title_full_unstemmed ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title_short ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
title_sort zsf1 rat as animal model for hfpef: development of reduced diastolic function and skeletal muscle dysfunction
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524062/
https://www.ncbi.nlm.nih.gov/pubmed/32710530
http://dx.doi.org/10.1002/ehf2.12915
work_keys_str_mv AT schauerantje zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT draskowskiruna zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT jannaschanett zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT kirchhoffvirginia zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT gotokeita zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT mannelanita zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT barthelpeggy zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT augsteinantje zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT winzerephraim zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT tugtekinmalte zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT labeitsiegfried zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT linkeaxel zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction
AT adamsvolker zsf1ratasanimalmodelforhfpefdevelopmentofreduceddiastolicfunctionandskeletalmuscledysfunction